In March this year, Marie Curie Cancer Care announced plans for a significant shift in the balance of its research portfolio.
Around £400m is spent every year in the UK on research into cancer prevention and cure, with less than £20m spent on end of life research.*
In its recently published strategy for end of life care in England, the Government said ‘more research is needed on all aspects of end of life care and on care given in different locations.’
The charity is proud of its fundamental research activities and the Marie Curie Research Institute. However going forward the charity will invest more in end-of life research and place less emphasis on fundamental scientific research.
As part of this new focus the charity is supporting the transition of its fundamental research providing funding for the next three years (until 2012) for MCRI scientists to enable the continuation of its scientific research in UK universities or research institutes.
Seven of the eight groups based at the Marie Curie Research Institute will be relocated to the following locations:
DNA replication laboratory, Group Leader, Jacob Z. Dalgaard PhD - Warwick University
Molecular motors laboratory, Group Leader, Rob Cross PhD – Warwick University
Chromosome Segregation Laboratory, Group Leader - Andrew McAinsh – Warwick University
Cytoskeletal Organization Laboratory, Group Leader - Anne Straube PhD - Warwick University
Protein trafficking and gene regulation, Group Leader - Peter O'Hare PhD - Imperial College
Cell Cycle Control Laboratory, Group Leader - Hiro Yamano, PhD - UCL
DNA Recombination Laboratory, Group Leader - Hideo Tsubouchi PhD - - Sussex University
Transcription, Group Leader - Thomas Oelgeschläger PhD, will not be relocated.
